Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective

Ainslie, Garrett R.; Davis, Myrtle; Ewart, Lorna; Lieberman, Linda A.; Rowlands, David J.; Thorley, Andrew J.; Yoder, Gorm; Ryan, Anne M.

doi:10.1039/c9lc00492k

Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective

Drug developers seek specific advancements in the development and qualification of microphysiological lung models for the evaluation of drug safety; here these essential elements are discussed from the perspective of the biopharmaceutical industry.